<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ANDROXY- fluoxymesterone tablet </strong><br>Upsher-Smith Laboratories Inc.<br></p></div>
<h1>ANDROXY™ (Fluoxymesterone Tablets, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">CIII</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">ANDROXY™</span> (Fluoxymesterone Tablets, USP) contains fluoxymesterone, a synthetic androgen.  The <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are steroids that develop and maintain primary and secondary male sex characteristics.  <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are derivatives of cyclopentano-perhydrophenanthrene.  Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are C-19 steroids with a side chain at C-17, and with two angular methyl groups.  Testosterone is the primary endogenous androgen.  Fluoxymesterone is a synthetic derivative of testosterone.</p>
<p>In their active form, all drugs in the class have a 17-beta-hydroxy group.  17-alpha-alkylation and halogenation at position 9 (fluoxymesterone) increase the pharmacologic activity per unit weight compared to testosterone when given orally.  Fluoxymesterone is a white or practically white odorless, crystalline powder, melting at about 240°C with some decomposition.  It is practically insoluble in water, sparingly soluble in alcohol and slightly soluble in chloroform.  Chemically fluoxymesterone is designated 9-fluoro-11β, 17β-dihydroxy-17-methylandrost-4-en-3-one.  Structurally it may be represented as follows:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5328c194-5650-4d1f-9e28-8cea038cce81&amp;name=androxy-01.jpg"></div>
<p><span class="Bold">ANDROXY™</span> (Fluoxymesterone Tablets, USP) for oral administration contains 10 mg of fluoxymesterone USP.</p>
<p>Inactive Ingredients:  croscarmellose sodium, D&amp;C Yellow #10 Aluminum Lake, FD&amp;C Blue #1 Aluminum Lake, FD&amp;C Yellow #6 Aluminum Lake, anhydrous lactose, magnesium stearate, microcrystalline cellulose, pregelatinized starch (corn), and sodium lauryl sulfate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics.  These effects include growth and maturation of prostate, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> also cause retention of nitrogen, sodium, potassium, and phosphorus, and decreased urinary excretion of calcium.  <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to increase protein anabolism and decrease protein catabolism.  Nitrogen balance is improved only when there is sufficient intake of calories and protein.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are responsible for the growth spurt of adolescence and for the eventual termination of linear growth which is brought about by fusion of the epiphyseal growth centers.  In children, exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> accelerate linear growth rates but may cause a disproportionate advancement in bone maturation.  Use over long periods may result in fusion of the epiphyseal growth centers and termination of growth process.  <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.</p>
<p>During exogenous administration of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH).  At large doses of exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).</p>
<p>There is a lack of substantial evidence that <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are effective in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, surgery, convalescence, and functional <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Testosterone given orally is metabolized by the gut, and 44 percent is cleared by the liver in the first pass.  Oral doses as high as 400 mg per day are needed to achieve clinically effective blood levels for full replacement therapy.  The 17-alpha-alkylated derivatives (fluoxymesterone and methyltestosterone) are less extensively metabolized by the liver and have longer half lives.  They are more suitable for oral administration than testosterone.</p>
<p>Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about two percent is free.  Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.</p>
<p>About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about six percent of a dose is excreted in the feces, mostly in the unconjugated form.  Inactivation of testosterone occurs primarily in the liver.  Testosterone is metabolized to various 17-keto steroids through two different pathways.  There are considerable variations of the half-life of testosterone as reported in the literature, ranging from 10 to 100 minutes.  The half-life of fluoxymesterone is reported to be 10 hours.</p>
<p>In responsive tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins.  The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IAU"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Males</h2>
<p class="First"><span class="Bold">ANDROXY™</span> Tablets are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1"></a><p></p>
<h3>Primary <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)</h3>
<p class="First">Testicular failure due to <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">cryptorchidism</span>, bilateral torsion, <span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>, vanishing testis syndrome, or orchidectomy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.2"></a><p></p>
<h3>Hypogonadotropic <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)</h3>
<p class="First">Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or radiation.  (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.)</p>
<p>If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics.  Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">Delayed puberty</span></h3>
<p class="First"><span class="Bold">ANDROXY™</span> (Fluoxymesterone Tablets, USP) may be used to stimulate puberty in carefully selected males with clearly <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>.  These patients usually have a familial pattern of <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date.  Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support.  The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration.  An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers <span class="Italics">(see <a href="#warnings">WARNINGS</a>)</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Females</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1"></a><p></p>
<h3>Metastatic mammary cancer</h3>
<p class="First"><span class="Bold">ANDROXY™</span> (Fluoxymesterone Tablets, USP) may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal.  Primary goals of therapy in these women include ablation of the ovaries.  Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy.  This treatment has been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.  Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contrain"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant.  When administered to pregnant women, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of the external genitalia of the female fetus.  This <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure.  The degree of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">masculinization</span> is related to the amount of drug given and the age of the fetus and is most likely to occur in the female fetus when the drugs are given in the first trimester.  If the patient becomes pregnant while taking <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, she should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">This drug has not been shown to be safe and effective for the enhancement of athletic performance.  Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.</p>
<p>In patients with breast cancer and in immobilized patients, androgen therapy may cause <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> by stimulating <span class="product-label-link" type="condition" conceptid="78308" conceptname="Osteolysis">osteolysis</span>.  In patients with cancer, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may indicate progression of bony <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span>.  If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, the drug should be discontinued and appropriate measures instituted.</p>
<p>Prolonged use of high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> has been associated with the development of <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> and <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasms</span> including hepatocellular carcinoma <span class="Italics">(see <a href="#pre_carcin">PRECAUTIONS, Carcinogenesis</a>)</span>.  <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">Peliosis hepatis</span> can be a life-threatening or fatal complication.</p>
<p><span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">Cholestatic hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occur with 17-alpha-alkylated <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> at a relatively low dose.  If <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> appears or if liver function tests become abnormal, the androgen should be discontinued and the etiology should be determined.  Drug-induced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> is reversible when the medication is discontinued.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk for the development of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma.</p>
<p>Due to sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may be a serious complication in patients with preexisting cardiac, renal, or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  In addition to discontinuation of the drug, diuretic therapy may be required.  If the administration of fluoxymesterone is restarted, a lower dosage should be used.</p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> frequently develops and occasionally persists in patients being treated for <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</p>
<p>Androgen therapy should be used cautiously in healthy males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>.  The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.  In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth.  This adverse effect may result in compromised adult stature.  The younger the child the greater the risk of compromising final mature height.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Women should be observed for signs of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> (deepening of the voice, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, clitoromegaly, and menstrual irregularities).  Discontinuation of drug therapy at the time of evidence of mild <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilism</span> is necessary to prevent irreversible <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>.  Such <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> is usual following androgen use at high doses and is not prevented by concomitant use of estrogens.  A decision may be made by the patient and the physician that some <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> will be tolerated during treatment for breast carcinoma.</p>
<p>Because <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may alter serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, caution should be used when administering these drugs to patients with a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.  Serial determinations of serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> should be made and therapy adjusted accordingly.  A causal relationship between <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Male adolescent patients receiving <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> for <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> should have bone development checked every six months.</p>
<p>The physician should instruct patients to report any of the following side effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<p><span class="Italics">Adult or adolescent males</span>—too frequent or persistent erections of the penis.</p>
<p><span class="Italics">Women—</span><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, changes in menstrual periods, or more facial hair.</p>
<p><span class="Italics">All patients—</span>Any <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color, or <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgen therapy <span class="Italics">(see <a href="#warnings">WARNINGS</a>)</span>.</p>
<p>Because of the hepatotoxicity associated with the use of 17-alpha-alkylated <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, liver function tests should be obtained periodically.</p>
<p>Periodic (every six months) X-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.</p>
<p>Hemoglobin and hematocrit should be checked periodically for <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span> in patients who are receiving high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">When administered concurrently, the following drugs may interact with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1"></a><p></p>
<h3>Anticoagulants, oral</h3>
<p class="First">C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirement.  Patients receiving oral anticoagulant therapy require close monitoring especially when <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are started or stopped.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.2"></a><p></p>
<h3>Antidiabetic drugs and insulin</h3>
<p class="First">In diabetic patients, the metabolic effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may decrease blood glucose and insulin requirements.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.3"></a><p></p>
<h3>ACTH and corticosteroids</h3>
<p class="First">Enhanced tendency toward <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.  Use caution when giving these drugs together, especially in patients with hepatic or cardiac disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.4"></a><p></p>
<h3>Oxyphenbutazone</h3>
<p class="First">May result in elevated serum levels of oxyphenbutazone.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may decrease levels of thyroxine-binding globulin, resulting in decreased total T<span class="Sub">4</span> serum levels and increased resin uptake of T<span class="Sub">3</span> and T<span class="Sub">4</span>.  Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="pre_carcin"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">Testosterone has been tested by subcutaneous injection and implantation in mice and rats.  The implant induced cervical-uterine tumors in mice, which metastasized in some cases.  There is suggestive evidence that injection of testosterone into some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of female mice increases their susceptibility to <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>.  Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically-induced carcinomas of the liver in rats.</p>
<p>There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> in high doses.  Withdrawal of the drugs did not lead to regression of the tumors in all cases.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk for the development of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.7.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1"></a><p></p>
<h4>Category X</h4>
<p class="First"><span class="Italics">(see <a href="#contrain">CONTRAINDICATIONS</a>)</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Androgen therapy should be used very cautiously in children and only by specialists who are aware of the adverse effects on bone maturation.  Skeletal maturation must be monitored every six months by an X-ray of the hand and wrist <span class="Italics">(see <a href="#IAU">INDICATIONS AND USAGE</a>, and <a href="#warnings">WARNINGS</a>)</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Endocrine and Urogenital, </span><span class="Italics">Female</span>—The most common side effects of androgen therapy are <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> and other menstrual irregularities, inhibition of gonadotropin secretion, and <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>, including deepening of the voice and clitoral enlargement.  The latter usually is not reversible after <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are discontinued.  When administered to a pregnant woman, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of external genitalia of the female fetus.</p>
<p><span class="Italics">Male—</span><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, and excessive frequency and duration of penile erections.  <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur at high dosages <span class="Italics">(see <a href="#CP">CLINICAL PHARMACOLOGY</a>)</span>.</p>
<p><span class="Bold">Skin and Appendages</span>—<span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4339092" conceptname="Male pattern alopecia">male pattern baldness</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
<p><span class="Bold">Fluid and Electrolyte Disturbances—</span>Retention of sodium, chloride, water, potassium, calcium <span class="Italics">(see <a href="#warnings">WARNINGS</a>)</span>, and <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">inorganic phosphates</span>.</p>
<p><span class="Bold">Gastrointestinal</span>—<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, alterations in liver function tests; rarely, hepatocellular neoplasms, <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span>, <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">(See <a href="#warnings">WARNINGS</a>)</span>.</p>
<p><span class="Bold">Hematologic—</span>Suppression of clotting factors II, V, VII, and X; <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients on concomitant anticoagulant therapy; and <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>.</p>
<p><span class="Bold">Nervous System</span>—Increased or decreased libido, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and generalized <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p><span class="Bold">Metabolic—</span>Increased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p><span class="Bold">Miscellaneous</span>—<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>; rarely, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"><span class="Bold">ANDROXY™</span> Tablets are classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no reports of acute overdosage with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">ANDROXY™</span> (Fluoxymesterone Tablets, USP), for oral administration, may be given as a single daily dose or in divided doses.  Dosage and duration of therapy will depend on age, sex, diagnosis, patient's response to treatment, and appearance of adverse effects.  The following recommendations will serve as a guide to therapy with <span class="Bold">ANDROXY™</span> Tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>In males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span></h2>
<p class="First">Various dosage regimens have been used, some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels.  Other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty.  The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.  Dosage is within the range of 2.5 to 20 mg daily, although generally in the lower range of 2.5 to 10 mg daily, and for a limited duration, for example 4 to 6 months.  X-rays should be taken at appropriate intervals to determine the amount of bone maturation and skeletal development <span class="Italics">(see <a href="#IAU">INDICATIONS AND USAGE</a>, and <a href="#warnings">WARNINGS</a>)</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Male <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span></h2>
<p class="First">As replacement therapy, i.e., for eunuchism, a daily dose of 5 to 20 mg is suggested.  It is usually preferable to start therapy at a higher level within the range (e.g., 10 mg), with subsequent adjustment as required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>Palliation of inoperable mammary cancer in women</h2>
<p class="First">A daily dose of 10 to 40 mg, given in divided doses, is recommended.  To determine if there will be an objective response, treatment should be continued for three months or more.  Patients must be followed closely because androgen therapy occasionally appears to accelerate the disease.  Thus, many experts prefer to use a shorter acting androgen preparation, such as <span class="Bold">ANDROXY™</span> Tablets, rather than those with prolonged activity, particularly during the early stages of androgen therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2>In palliation of advanced mammary carcinoma</h2>
<p class="First">Hormone therapy is adjunctive to and not a replacement for conventional therapy.  Duration of therapy will depend on the response of the condition and the appearance of adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">ANDROXY™</span> (Fluoxymesterone Tablets, USP) 10 mg are round, green, scored compressed tablets debossed with 832 and 86 and are available in bottles of 100.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store at controlled room temperature 15 – 30°C (59 – 86°F).</p>
<p><span class="Bold">Keep out of reach of children.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">Manufactured by<br><span class="Bold">UPSHER-SMITH LABORATORIES, INC.</span><br>Maple Grove, MN  55369</p>
<p>Rev 0713</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label</h1>
<p class="First">NDC 0832-0086-00<br><span class="Bold">CIII</span></p>
<p><span class="Bold">ANDROXY™<br>Fluoxymesterone<br>Tablets, USP</span></p>
<p><span class="Bold">10 mg</span></p>
<p>100 Tablets<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">UPSHER-SMITH</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5328c194-5650-4d1f-9e28-8cea038cce81&amp;name=androxy-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ANDROXY 		
					</strong><br><span class="contentTableReg">fluoxymesterone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0832-0086</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fluoxymesterone</strong> (fluoxymesterone) </td>
<td class="formItem">fluoxymesterone</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Yellow No. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>aluminum oxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">832;86</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0832-0086-00</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088342</td>
<td class="formItem">10/21/1983</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Upsher-Smith Laboratories Inc.
							(809088862)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Upsher-Smith Laboratories Inc.</td>
<td class="formItem"></td>
<td class="formItem">809088862</td>
<td class="formItem">MANUFACTURE(0832-0086)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Upsher-Smith Laboratories Inc.</td>
<td class="formItem"></td>
<td class="formItem">079111820</td>
<td class="formItem">PACK(0832-0086), LABEL(0832-0086)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Upsher-Smith Laboratories Inc.</td>
<td class="formItem"></td>
<td class="formItem">047251004</td>
<td class="formItem">ANALYSIS(0832-0086)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>29955938-cd02-4589-9df7-3bab841b1c58</div>
<div>Set id: 5328c194-5650-4d1f-9e28-8cea038cce81</div>
<div>Version: 3</div>
<div>Effective Time: 20141006</div>
</div>
</div> <div class="DistributorName">Upsher-Smith Laboratories Inc.</div></p>
</body></html>
